Telemonitoring for cancer patients receiving treatment
A Study of the Benefit of Telemonitoring for Hospital Staff Treating Patients With Oral or Intravenous Cancer Treatments: a French Prospective, Randomized, Unblinded, Single-centre Study.
NA · Centre Hospitalier de Bligny · NCT06381024
This study is testing if using a telemonitoring app along with regular care can help cancer patients starting treatment feel better and catch side effects earlier.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 82 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier de Bligny (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Briis-sous-Forges) |
| Trial ID | NCT06381024 on ClinicalTrials.gov |
What this trial studies
This interventional study aims to evaluate the effectiveness of integrating telemonitoring with standard care for cancer patients starting oral or intravenous treatment. Participants will be randomly assigned to receive either standard care alone or standard care supplemented with the Cureety telemonitoring application. The study will track the number of phone calls made during the first four months of treatment, as well as collect data on quality of life and patient satisfaction through questionnaires. The goal is to enhance patient management and early detection of side effects while reducing unnecessary healthcare interactions.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are initiating oral or intravenous cancer treatment and can use the Cureety application.
Not a fit: Patients who have received cancer treatment at the Centre Hospitalier de Bligny in the last five years will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve patient monitoring and reduce the need for frequent phone calls, enhancing the overall treatment experience.
How similar studies have performed: Previous studies have shown promising results with telemonitoring in cancer care, indicating potential benefits for both patients and healthcare providers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients that have provide written informed consent for study participation. 2. Patients aged 18 years or older. 3. Patients initiating oral or intravenous treatment (chemotherapy, immunotherapy, targeted therapies etc.) for localized or metastatic or recurrent cancer treated at the CH Bligny. 4. Patients with the capacity, personally (e.g., language and capacity to use the application), and in terms of infrastructure (internet access, possessing a smart phone etc.) to perform telemonitoring with Cureety. 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 Exclusion Criteria: * Patients treated for cancer at the CH Bligny in the last 5 years
Where this trial is running
Briis-sous-Forges
- Centre Hospitalier de Bligny — Briis-sous-Forges, France (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, remote patient monitoring